The results of preclinical behavioral pharmacology experiments suggest that atypical antipsychotics like risperidone, olanzapine, and clozapine consistently attenuate the discriminativestimulus effects of amphetamine (Arnt, 1992 (Arnt, , 1996 Kilbey and Ellinwood, 1979; Mechanic et al., 2002; Nielsen and Jepsen, 1985; Meert, 1991 Meert, , 1996 . In one experiment, the discriminative stimulus effects of d-amphetamine (1.0 mg/kg) were tested alone and following pretreament with risperidone (0.04-2.5 mg/kg), olanzapine (0.0025-2.5 mg/kg), and clozapine (0.08-2.5 mg/kg) in rats trained to discriminate 1.0-mg/kg d-amphetamine (Arnt, 1996) . Risperidone, olanzapine, and clozapine dose dependently decreased percent drug-appropriate responding. The results of these experiments suggest that these antipsychotics, which are mixed D 2 and 5-HT 2 antagonists (for reviews, see Fitton and Heel, 1990; Fulton and Goa, 1997; Grant and Fitton, 1994) , block some of the behavioral effects of d-amphetamine that may contribute to its abuse.
Despite these provocative preclinical data, we know of only one human laboratory experiment in which the effects of amphetamine were examined following pretreatment with an atypical antipsychotic (Wachtel et al., 2002) . In this experiment, the acute self-reported effects of a This article has not been copyedited and formatted. The final version may differ from this version. Risperidone pretreatment did not alter the self-reported effects of methamphetamine.
The reason for the discrepancy between experiments conducted with animals and humans is unknown, but may be attributable to the use of different methods. As noted above, the experiments conducted with animals assessed the discriminative-stimulus or reinforcing effects of amphetamine following pretreatment with risperidone, olanzapine, or clozapine. The only available study conducted with humans assessed the self-reported effects of amphetamine following pretreatment with risperidone. While the discriminative-stimulus or reinforcing effects of drugs and their selfreported effects overlap, they are not isomorphic and can be dissociated (e.g., Rush et al., 1998 Rush et al., , 2002 .
Drug-discrimination procedures commonly used with laboratory animals have been adapted for use with humans . While the discriminative-stimulus effects of amphetamine following pretreatment with atypical antipsychotics have been studied in laboratory animals, comparable studies in humans do not exist. The present experiment was designed to assess the discriminative-stimulus effects of d-amphetamine (0-15 mg), alone and following pretreatment with risperidone (0 and 1 mg), in humans that had learned to discriminate 15-mg d-amphetamine. dAmphetamine is reliably discriminated by humans (Chait and Johanson, 1988; Chait et al. 1986a Chait et al. , 1986b Heishman and Henningfield, 1991; Kollins and Rush, 1999; Rush et al. 1998) . The dose of risperidone studied, 1 mg, was chosen because it is the recommend initial acute dose (Physician's Desk Reference [PDR], 2003) . We examined the discriminative-stimulus effects of d- 
Methods

Participants
Ten healthy adults were recruited via newspaper ads, flyers and word-of-mouth to participate in this experiment. Participants were paid $40/session to participate in this experiment and received performance-based payment as outlined below. One participant was unable to accurately discriminate 15 mg d-amphetamine, while another participant was discharged for medical reasons unrelated to the study medications. Data from these participants were not included in the analyses. Eight participants (4 males, 4 females) completed this experiment. These participants ranged in age from 18 to 28 years (mean = 23), and in weight from 57 to 95 kg (mean = 71). These participants reported consuming 9
to 508 mg caffeine/day (mean = 157), and had completed 14 to 18 years of education (mean = 16).
One participant reported smoking 12-tobacco cigarettes/day. This participant was allowed to have one cigarette approximately midway through the experimental session. Participants completed questionnaires assessing drug use, medical and psychiatric histories, and provided written informed consent prior to participating. Individuals with current or past histories of serious psychiatric disorder, including substance abuse/dependence disorders, were excluded from participating. All participants were in good health with no contraindications to stimulant or antipsychotic medications.
Drug urine screens conducted during screening were negative for amphetamine, benzodiazepines, barbiturates, cocaine and opioids (Abuscreen ONTRAK, Roche Diagnostic Systems, Nutley, NJ).
One participant tested positive for tetrahydrocannibinol (THC). In the female participants, urine pregnancy tests before and periodically during study participation were negative. The Institutional
Review Board of the University of Kentucky Medical Center approved this study and the informed consent document.
This article has not been copyedited and formatted. The final version may differ from this version. antipsychotics. Participants were told that the purpose of the study was to see if they could tell the difference between various drugs, and how these drugs affect mood and behavior. Other than receiving this general information participants were blind to the type of drug administered, and were given no instructions regarding what they were "supposed" to do or what outcomes might be expected.
Prior to initiating medication testing, participants completed two "practice" sessions. These "practice" sessions were used to familiarize participants with the drug-discrimination task, selfreported drug-effect questionnaires, performance measure, and daily laboratory routine. No medications were administered on these days.
Throughout the study, participants were requested to refrain from using all illicit psychoactive drugs, caffeine and solid food for 4 hours prior to a scheduled experimental session, and alcohol for 12 hours prior to a scheduled experimental session. On each experimental-session day, participants arrived at the laboratory and provided a urine sample each session before drug administration, which was screened for the presence of amphetamine, barbiturates, benzodiazepines, cocaine, opioids and THC. These urine samples were occasionally positive for amphetamine, which was likely due to the administration of the experimental medications. One participants' urine specimen was positive for THC five times during the conduct of this experiment, while another participants' urine specimen was positive for THC on one occasion. Yet another participant's urine specimen was positive for opioids On experimental-session days, participants completed the self-reported drug-effect questionnaires and performance task approximately 30 minutes before drug administration, and then completed the drug-discrimination task, self-reported drug-effect questionnaires and performance task 1, 2, 3, 4, and 5 hours after drug administration. When not completing the drug-discrimination task, self-reported questionnaires and performance task, participants were allowed to engage in recreational activities (e.g., watch television, play cards or read) or socialize with each other.
Drug Discrimination Procedures
This experiment consisted of three phases, which were completed in fixed order: 1) sampling phase, 2) acquisition phase, and 3) test phase.
Sampling Phase. All participants completed two sampling sessions to acquaint them with the drug effects. Participants reported to the laboratory and completed the self-reported drug-effect questionnaires and performance task (described below). During each sampling session, participants ingested four capsules that contained a total of 15 mg d-amphetamine. d-Amphetamine was identified by letter code (e.g., DRUG A), but the participants were not explicitly informed of the capsules' contents. Below are the instructions given to each participant during the sampling phase.
These instructions were printed on a piece of paper and participants were instructed to carefully read them prior to each sampling session. A research assistant also read these instructions aloud. mg d-amphetamine (e.g., DRUG A) or placebo (e.g., NOT DRUG A). Participants were not explicitly instructed that they would be attempting to acquire a drug versus placebo discrimination. After capsule administration, participants completed the drug-discrimination task, self-reported drug-effect questionnaires and performance measure periodically for five hours. Participants were instructed that they could change their responses on the drug-discrimination task between hours 1, 2, 3, 4, and 5 based on what they believed at the time. After completing the drug-discrimination task, self-reported drug-effect questionnaires and performance task at the five-hour observation, participants opened a sealed envelope that informed the participant and the research assistant of the identity of the drug administered (i.e., DRUG A or NOT DRUG A). The criterion for having acquired the discrimination was ≥ 80% correct responding on four consecutive sessions on the drug-discrimination task described Below are the instructions given to each participant during the test-of-acquisition phase. These instructions were printed on a piece of paper and participants were told to carefully read them prior to each experimental session. A research assistant also read these instructions aloud. These instructions were also used during the test phase described below.
Instructions (Acquisition Phase)
. Today we will not tell you whether you received At the end of today's session, you will be given an envelope that will tell you if you received Drug A or Not Drug A. The number of points that you accumulated on the correct button will then be converted to money and you will be told how much bonus money you earned during today's session. At the end of some sessions, we may not be able to tell you whether you received Drug A or Not Drug A. On the days that we cannot tell whether you received Drug A or Not Drug A, your bonus This article has not been copyedited and formatted. The final version may differ from this version. were test days, and the remainder acquisition days. As noted above, participants were instructed that there would be days on which they would not be given any feedback concerning the accuracy of their drug-discrimination performance, and that on these days they would be credited with the greater number of points allocated to the DRUG A or NOT DRUG A option. Thus, these days were similar to the acquisition days except that participants did not receive any feedback concerning their drugdiscrimination performance and they earned the bonus money allocated to DRUG A or NOT DRUG A, whichever was greater. Participants were not told the purpose of these "test" days, nor did they know when they were scheduled until after they opened the sealed envelope.
To ensure that participants continued to reliably discriminate 15 mg d-amphetamine throughout the test phase, acquisition days were intermixed among the test days. These test-of-acquisition days were identical to those in the acquisition phase (i.e., participants received 15 mg d-amphetamine or placebo), completed the drug-discrimination task periodically for five hours after drug administration, were informed whether they had received DRUG A or NOT DRUG A, and received bonus money contingent on the accuracy of their drug-discrimination performance. If a participant responded incorrectly on a test-of-acquisition day (i.e., ≤ 80% correct), additional test-of-acquisition days were scheduled. These additional test-of-acquisition days continued until the participant correctly identified both conditions once (i.e., 15 mg d-amphetamine and placebo). the experiment was random except that an active drug dose was never administered on more than three consecutive sessions.
Drug-Discrimination Measure
A point-distribution drug-discrimination task was completed 1, 2, 3, 4, and 5 hours after oral drug administration on an Apple Macintosh microcomputer (Apple Computer, Inc., Cupertino, CA).
In this procedure, the participant distributed 100 points between two options (i.e., DRUG A or NOT DRUG A) (Rush and Baker, 2001; Rush et al. 2002) . Points accumulated on the correct option were exchangeable for money at a rate of $0.08/point. Thus, participants were able to earn a maximum of $40.00/session on this task. The dependent measure in this procedure was percent d-amphetamineappropriate responding.
Self-reported Questionnaires, Performance Task and Physiological Measures
Self-reported drug-effect questionnaires were administered on an Apple Macintosh microcomputer. The self-reported drug-effect questionnaires were completed in fixed order. These questionnaires were completed approximately 30 minutes before drug administration, and 1, 2, 3, 4, and 5 hours after drug administration.
Stimulant-Sensitive Adjective-Rating Scale. The stimulant-sensitive adjective-rating scale consisted of 21 items that have previously been shown to be sensitive to acute oral administrations of commonly abused stimulants (Di Marino et al. 1998; Rush and Baker, 2001; Rush et al. 2002) .
Participants rated each item using the computer mouse to point to and select among one of five numerically from 0 to 4, respectively). Responses to individual items were summed to produce a total score, so the maximum possible score was 84.
Adjective-Rating Scale. The adjective rating scale consisted of 32 items and contained two subscales: Sedative and Stimulant (Oliveto et al. 1992) . Participants rated each of the items using a 5-point scale similar to the one described above. Out). Responses to individual items were summed to produce a composite score for each subscale.
The maximum possible score on each subscale was 64. Digit-Symbol-Substitution Test (DSST). A computerized version of the DSST, which has been described previously, was used in this experiment (McLeod et al. 1982) . Briefly, participants used a numeric keypad to enter a geometric pattern associated with one of nine digits displayed on a video screen. Participants had 90 seconds to enter as many geometric patterns as possible. The dependent measure was the number of patterns the participant entered correctly (i.e., trials correct).
Heart Rate and Blood Pressure. Heart rate and blood pressure were recorded using an automated blood-pressure monitor (DINAMAP XL, Johnson and Johnson, Alexandria, TX). Heart rate and blood pressure were monitored for approximately 30 minutes before drug administration and at hourly intervals for five hours afterwards. Heart rate and blood pressure were recorded immediately before participants completed the drug-discrimination, self-reported drug-effect questionnaires, and performance task. The behavioral effects of d-amphetamine peak approximately two to three hours after oral administration (Chait et al. 1985 (Chait et al. , 1986a (Chait et al. , 1986b Rush et al. 1998) . Peak risperidone plasma
concentrations occur approximately one hour after oral administration (Grant and Fitton, 1994; Gupta et al. 1994; Keegan, 1994) . Peak 9-hydroxyrisperidone concentrations occur approximately three hours after oral administration (Gupta et al. 1994) . The antipsychotic effects likely result from the combined concentrations of risperidone and 9-hydroxyrisperidone (Grant and Fitton, 1994; Gupta et al. 1994; Keegan, 1994) . Based on these pharmacokinetic data, d-amphetamine and risperidone were administered simultaneously to assess behavioral effects across peak plasma levels of both drugs.
References below to placebo pertain to sessions in which placebo doses of both d-amphetamine and risperidone were administered. References to d-amphetamine alone pertain to sessions in which an active dose of d-amphetamine was administered in combination with 0-mg risperidone.
References to risperidone alone pertain to sessions in which the active dose of risperidone was administered in combination with 0-mg d-amphetamine .
Data Analysis
Statistical analyses of group data were conducted to examine drug effects on the drugdiscrimination task, self-reported drug-effect questionnaires, and performance measure. Data were analyzed statistically as raw scores. To correct for multiple comparisons and maintain consistency across measures, effects were considered significant for p 
Discussion
In the present experiment, the discriminative-stimulus and self-reported effects of d-amphetamine
were assessed alone and following pretreatment with risperidone in d-amphetamine-trained humans.
d-Amphetamine alone functioned as a discriminative-stimulus and dose-dependently increased drugappropriate responding. d-Amphetamine alone also produced stimulant-like self-reported drug effects (e.g., increased ratings of Like Drug) that were generally dose dependent. These findings are concordant with the results of several previous reports in which the discriminative-stimulus and selfreported effects of d-amphetamine were assessed in humans (Chait and Johanson, 1988; Chait et al. 1984 Chait et al. ,1985 Chait et al. , 1986a Chait et al. , 1986b Heishman and Henningfield, 1991; Kollins and Rush, 1999; Lamb and Henningfield, 1994; Rush et al. 1998 ).
Risperidone alone did not occasion d-amphetamine-appropriate responding, nor did it produce significant increases on self-reported indices thought to measure sedation (e.g., PCAG scores of the ARCI). The results of the present experiment are concordant with those from a previous study in which 0.75-mg risperidone alone did not significantly increase PCAG scores (Wachtel et al. 2002) .
Risperidone alone significantly impaired performance on a computerized version of the DSST which is concordant with the results of a previous study in which 0.75 mg risperidone impaired performance on a paper-and-pencil version of the DSST (Wachtel et al. 2002) .
Risperidone pretreatment significantly attenuated the discriminative-stimulus effects of damphetamine. While the discriminative-stimulus effects of d-amphetamine following pretreatment with various atypical antipsychotics have been widely studied in laboratory animals (Arnt, 1992 (Arnt, , 1996 Kilbey and Ellinwood, 1979; Mechanic et al., 2002; Nielsen and Jepsen, 1985; Meert, 1991 Meert, , 1996 , we are unaware of any published studies in which a similar strategy was used with humans.
The results of the present human laboratory experiment are concordant with those from previous studies in which the discriminative-stimulus effects of d-amphetamine were assessed alone and following risperidone pretreatment in amphetamine-trained rats (Meert, 1991 (Meert, , 1996 . In these experiment, rats were trained to discriminate 1.25-mg/kg d-amphetamine. As expected, damphetamine (0.08-0.63 mg/kg) dose dependently increased the number of rats selecting the drug lever. Risperidone (0.05-1.25 mg/kg) dose-dependently decreased the number of rats selecting the drug lever after administration of 1.25-mg/kg d-amphetamine. Worth noting is that the highest dose of risperidone tested completely blocked the discriminative-stimulus effects of 1.25 mg/kg damphetamine. We are not aware of any published reports in which the discriminative-stimulus effects of d-amphetamine were assessed alone and following pretreatment with risperidone in primates.
As mentioned above, risperidone is an antagonist at the D 2 dopamine and 5-HT 2 receptors (for reviews, see Grant and Fitton, 1994; Gupta et al., 1994; Keegan, 1994) . Future studies with humans should compare the discriminative-stimulus effects of d-amphetamine following pretreatment with a more selective D 2 dopamine (e.g., haloperidol) and 5-HT 2 serotonin (e.g., ritanserin) antagonist to discern the relative contribution of dopamine or serotonin. Such experiments would more clearly determine the neuropharmacological factors that mediate the behavioral effects of stimulants in humans and might guide the development of a pharmacotherapy for the treatment of stimulant abuse/dependence.
Risperidone pretreatment also significantly attenuated some of the self-reported effects of damphetamine (e.g., ratings Willing to Take Again and Like Drug on the Drug-Effect Questionnaire).
The present findings are discordant with the results from a previously published study in which the effects of methamphetamine (0 and 20 mg) were assessed following pretreatment with risperidone (0 and 0.75 mg) (Wachtel et al. 2002) . In this previous study, risperidone pretreatment did not alter the self-reported effects of methamphetamine to a statistically significant degree. The reason for the discrepancy between the results of this previous report and the present experiment is unknown, but may be due to the use of different methods. First, and perhaps most notably, participants in the This article has not been copyedited and formatted. The final version may differ from this version. relative to the dose of methamphetamine (i.e., 20 mg) that was used in the previous study. dAmphetamine and methamphetamine are approximately equipotent (Lamb and Henningfield, 1994) .
Future studies should also determine whether risperidone attenuates the self-reported effects of higher d-amphetamine doses under conditions similar to those used in the present experiment. Ideally, a future study should assess the self-reported effects of a wide range of doses of d-amphetamine alone and following pretreatment with several doses of risperidone under experimental conditions similar to those used in the present experiment. However, the conduct of such a study with humans would present both ethical (i.e., increased number of drug exposures) and practical problems (i.e., participant attrition) (Fischman and Johanson, 1998) .
While pretreating participants with risperidone significantly attenuated some of the self-reported effects of d-amphetamine, this effect was not observed on other self-reported drug-effect measures (e.g., A and MBG scores on the ARCI). The A and MBG scales of the ARCI are widely used instruments that are sensitive to the acute effects of stimulants (Heishman and Henningfield, 1991; Lamb and Henningfield, 1994; Rush and Baker, 2001; Wachtel et al. 2002) . The failure of of methamphetamine-risperidone combinations were examined (Wachtel et al. 2002) . The results of the present experiment along with those from this previous study suggest that the ARCI may have limited utility for examining the combined effects of an agonist and antagonist.
We are aware of only two published studies in which the discriminative-stimulus and self-reported effects of a stimulant drug were assessed following pretreatment with an antagonist (Oliveto et al. 1997; Perkins et al. 1999 ). In the first study, six participants were trained to discriminate between caffeine (320-mg/70 kg) and placebo (Oliveto et al. 1997) . Future studies should use other drug-discrimination tasks like the novel-response procedure because combining d-amphetamine and risperidone may have produced a unique stimulus complex ). The novel-response procedure provides an alternative for drug effects that are unlike those of the training drugs (e.g., d-amphetamine and placebo), and may be more sensitive for detecting differences between the discriminative-stimulus effects of agonist-antagonists combinations.
Finally, the results of the present experiment suggest that risperidone might be an effective pharmacotherapy for the treatment of stimulant abuse/dependence. However, the results of a rigorous clinical trial suggest that risperidone (2, 4, and 8 mg once daily in the evening) was not effective in reducing drug use or improving retention in treatment in cocaine-dependent patients relative to placebo (Grabowski et al. 2000) . In fact, 4 and 8-mg risperidone reduced treatment retention below levels observed with placebo and the trial was terminated after conducting an interim analysis. 
